KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Notes Payables: 2009-2017

Historic Notes Payables for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Dec 2017 value amounting to $1.0 million.

  • Teva Pharmaceutical Industries' Notes Payables fell 93.33% to $1.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.0 million, marking a year-over-year decrease of 93.33%. This contributed to the annual value of $1.0 million for FY2017, which is 93.33% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Notes Payables of $1.0 million as of FY2017, which was down 93.33% from $15.0 million recorded in FY2016.
  • In the past 5 years, Teva Pharmaceutical Industries' Notes Payables ranged from a high of $850.0 million in FY2013 and a low of $1.0 million during FY2017.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Notes Payables value was $15.0 million (recorded in 2016), while the average stood at $30.3 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Notes Payables plummeted by 94.59% in 2014 and then surged by 63.04% in 2015.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Notes Payables stood at $850.0 million in 2013, then tumbled by 94.59% to $46.0 million in 2014, then skyrocketed by 63.04% to $75.0 million in 2015, then tumbled by 80.00% to $15.0 million in 2016, then slumped by 93.33% to $1.0 million in 2017.